Sodium butyrate with UCN-01 has marked antitumour activity against cervical cancer cells.
Fiche publication
Date publication
octobre 2010
Journal
Anticancer research
Auteurs
Membres identifiés du Cancéropôle Est :
Dr MARCHINI Antonio, Pr PRETET Jean-Luc
Tous les auteurs :
Decrion-Barthod AZ, Bosset M, Plissonnier ML, Marchini A, Nicolier M, Launay S, Prétet JL, Rommelaere J, Mougin C
Lien Pubmed
Résumé
The effect of combining sodium butyrate (NaB), a histone deacetylase inhibitor, and 7-hydroxy-staurosporine (UCN-01) on cytotoxicity in human cervical carcinoma cells was evaluated.
Mots clés
Animals, Antineoplastic Combined Chemotherapy Protocols, pharmacology, Apoptosis, drug effects, Butyrates, administration & dosage, Cell Cycle, drug effects, Cell Growth Processes, drug effects, Cell Line, Tumor, Female, HeLa Cells, Human papillomavirus 16, isolation & purification, Human papillomavirus 18, isolation & purification, Humans, Mice, Mice, Nude, Papillomavirus Infections, pathology, Staurosporine, administration & dosage, Uterine Cervical Neoplasms, drug therapy, Xenograft Model Antitumor Assays
Référence
Anticancer Res.. 2010 Oct;30(10):4049-61